To evaluate the cardiovascular and plasma catecholamine responses to dynamic exercise in patients with cardiac neurosis (CN), treadmill testing was performed. Thirty-four patients with CNwere chosen for this study based on exercise tolerance and the results were compared with those in 31 patients with organic heart disease and 12 normal subjects. Patients with CNshowed an augmentation of cardiovascular and plasma catecholamine responses. The augmentation of the norepinephrine response in patients with CNwas not as remarkable as that in patients with organic heart disease. Onthe other hand, the augmentation of the epinephrine response was greater in patients with CNthan in those with organic heart disease. Administration of metoprolol (40 mg/day) for two weeks improved exercise tolerance in patients with CN.Wesuggest that anxiety augments both sympatho-neural and sympatho-adrenal activity and that it is the symptoms induced by the augmented cardiovascular response which reduce exercise tolerance in patients with CN.
Cardiac neurosis (CN) is a psychophysiological syndrome characterized
by cardiovascular and nervous symptoms in the absence of underlying organic disorders. This syndrome is regarded to be similar to irritable heart syndrome (1), soldier' s heart, effort syndrome, hyperkinetic heart syndrome (2), hyperdynamic beta-adrenergic circulatory state (3), and neurocirculatory asthenia. Dyspnea, palpitation and nervousnessare common symptoms both at rest and during effort. This condition is assumed to be a hyperkinetic cardiovascular state based on anxiety. Sympathetic activity has an important role in cardiovascular response to a variety of stress types. Previous studies (4-6) showed an increase in plasma catecholamine concentrations in patients with panic and anxiety disorders. However, few reports have been published on the plasma catecholamine response to dynamic exercise in patients with CNand in these reports the results do not agree (7-9). The purpose of this study was to investigate whether or not the characteristic response of plasma catecholamines to dynamic exercise occurs in patients with CN. Therefore, the cardiovascular and plasma catecholamine responses during treadmill exercise testing were evaluated in patients with CN and the results were compared with those in patients with organic heart disease and in normal subjects.
Additionally, the effects of blockade of betaadrenergic receptors on exercise tolerance was evaluated.
METHODS

Su bjects
Westudied 34 patients (ll men, 23 women; mean age 48 ± 13 years) with symptoms characteristic of CN(dyspnea, palpitation, nervousness and anxiousness), 31 patients (ll men, 20 women; mean age 53± 10 years) with organic heart disease, and 12 normal subjects (8 men, 4 women; mean age 42± 14 years). 
RESULTS
Exercise tolerance (Table 1) Of 34 patients with CN, 13 had poor tolerance, 10 had fair tolerance, and ll had good tolerance. Of 31 patients with organic heart disease, 20 had poor tolerance, and ll had fair tolerance. All 12 normal subjects had good tolerance. Then heart rate, systolic blood pressure, plasma norepinephrine and epinephrine concentrations at rest and at the peak exercise in both patient groups with poor tolerance were compared with those at rest and at the end of the second exercise stage in normal subjects, respectively. The results at rest and at the peak exercise in both patient groups with fair tolerance were comparedwith those at rest and at the end of the third exercise stage in normal subjects, respectively. Andthe results at rest and at the peak exercise in the CNpatient group with good tolerance were comparedwith those at rest and at the peak exercise in normal subjects, respectively.
Heart rate ( Heart rate (HR) at rest was significantly higher in the poor tolerance CNgroup than in normal subjects. HRat the peak exercise in both patient groups with poor tolerance (CN, 140 ± 16; organic heart disease, 134 ± 19 beats/min) was significantly higher than that at the end of the second exercise stage in normal subjects (102± 13 beats/min). HR at the peak exercise in both patient groups with fair tolerance (CN, 145± 13; organic heart disease, 135 ±20 beats/min) was significantly higher than that at the end of the third exercise stage in normal subjects (118± ll beats/min)0 And there was no significant difference in HRat the peak exercise between the good tolerance CNgroup (147± 15 beats/min) and normal subjects (148± 15 beats/ min).
Systolic blood pressure (Fig. 2)
The systolic blood pressure (SBP) of patients with CNand that of normal subjects was comparedas the SBP response is influenced by organic heart disease. SBPat rest and at the peak exercise in the poor tolerance CN group (exercise, 167 ± 25 mmHg) was significantly higher than that at rest and at the end of the second exercise stage in normal subjects (exercise, 134± 17 mmHg), respectively. SBP at the peak exercise in the fair tolerance CN group (170± 35 mmHg)tended to be higher than that at the end of the third exercise stage in normal subjects Patients were grouped based on exercise tolerance (poor, fair or good). HRat the peak exercise in patient groups was comparedwith that at the equivalent level of exercise (at the end of the second or third exercise stage or at the peak exercise) in normal subjects. *p<0.05. the good tolerance CN group (171 ± 16 mmHg) and normal subjects (162± 14 mmHg).
Plasma norepinephrine concentration (Fig. 3) There was no significant difference in plasma norepinephrine (NE) concentration at rest between the poor tolerance CNgroup (152 ± 52 pg/ml) and normal subjects (123 ± 37 pg/ml). Plasma NE concentration at rest was significantly higher in the poor tolerance organic heart disease group (223 ± 115 pg/ml) than in either the poor tolerance CNgroup or normal subjects. Plasma NEconcentration at the peak exercise in both patient groups with poor tolerance (CN, 675 ±357; organic heart disease, 954 ± 488 pg/ml) was significantly higher than that at the end of the second exercise stage in normal subjects (265 ± 79 pg/ml). There was no significant difference in plasma NEconcentration at the peak exercise between both patient groups with poor tolerance. There were no significant differences in plasma NEconcentration at rest amongpatient groups with fair tolerance (CN, 146± 51; organic heart disease, 180 ± 85 pg/ml) and normal subjects. Plasma NEconcentration at the peak exercise in the fair tolerance CN group (676±279 pg/ml) was significantly higher than that at the end of the third exercise stage in normal subjects (305 ± 90 pg/ml). Plasma NEconcentration at the peak exercise in the fair tolerance organic heart disease group (1 135 ± 517 pg/ml) was significantly higher than that at the equivalent level of exercise in the fair tolerance CN group and in normal subjects. And plasma NE concentration at the peak exercise wassignificantly higher in the good tolerance CN group (724± 321 pg/ml) than in normal subjects (461 ± 169 pg/ml), while there was no significant difference in plasma
NEconcentration at rest between these two groups (CN, 130±28 pg/ml).
Plasma epinephrine concentration (Fig. 4) Plasma epinephrine (E) concentration at rest was significantly higher in the poor tolerance CNgroup (45±36 pg/ml) than in normal subjects (22± ll pg/ml). Plasma E concentration at rest in the poor tolerance organic heart disease group (25 ± 24 pg/ml) was not significantly different from that at rest in the poor tolerance CNgroup or in normal subjects. Plasma E concentration at the peak exercise in the poor tolerance CN group (108±66 pg/ml) was significantly higher than that at the peak exercise in the poor tolerance organic heart disease group (48 ± 25 pg/ml) and at the end of the second exercise stage in normal subjects (28 ± 19 pg/ml). Plasma E concentration at the peak exercise in the poor tolerance organic heart disease group was not significantly different from that at the end of the Patients were grouped based on exercise tolerance. Plasma E concentration at the peak exercise in patient groups was compared with that at the equivalent level of exercise in normal subjects. *p<0.05.
second exercise stage in normal subjects. There were no significant differences in plasma E concentration at rest among patient groups with fair tolerance (CN, 19± 12; organic heart disease, 20± 10 pg/ml) and normal subjects. Plasma E concentration at the peak exercise in the fair tolerance CN group (75±44 pg/ml) tended to be higher than that at the end of the third exercise stage in normal subjects (44 ± 23 pg/ml) (p <0.1). Plasma E concentration at the peak exercise in the fair tolerance organic heart disease group (59 ± 46 pg/ml) was not significantly different from that at the peak exercise in the fair tolerance CNgroup and at the end of the third exercise stage in normal subjects.
There was no significant difference in plasma E concentration either at rest or at the peak exercise between the good tolerance CNgroup (rest, 22± 12; exercise, 65 ± 33 pg/ml) and normal subjects (exercise, 53 ± 24 pg/ml).
Changes in plasma norepinephrine concentration
The change in plasma NE concentration ( A NE) was measured by comparing plasma NEconcentration at rest with the value at the peak exercise in patients with CN and those with organic heart disease, and by comparing plasma NE concentration at rest with the value at the end of the second or third exercise stage, or at the peak exercise in normal subjects. There was no significant difference in A NE between the patient groups with poor tolerance (CN, 522±324; organic heart disease, 724±447 pg/ml). A NE in both patient groups with poor tolerance was significantly higher than that at the end of the second exercise stage in normal subjects (143±53 pg/ml). A NE in the fair tolerance CN group (537±236 pg/ml) was significantly higher than that at the end of the third exercise stage in normal subjects (188 ± 71 pg/ml). A NE in the fair tolerance organic heart disease group (955 ±479 pg/ml) was significantly higher than that in the fair tolerance CNgroup and that at the end of the third exercise stage in normal subjects. A NE in the good tolerance CNgroup (594 ± 329 pg/ml) was not significantly different from that at the peak exercise in normal subjects (378 ± 150 pg/ml).
Changes in plasma epinephrine concentration (Fig. 6)
The change in plasma E concentration ( A E) was measured inthe samemanner as A NE. A Einthe poor tolerance CN group (64±52 pg/ml) was significantly higher than that in the poor tolerance organic heart disease group (25 ± 19 pg/ml) and that at the end of the second exercise stage in normal subjects (7 ± 13 pg/ml). A E in the poor tolerance organic heart disease group was significantly higher than that at the end of the second exercise stage in normal subjects. There was no significant difference in A E between the patient groups with fair ( A E) during multistage treadmill exercise in patients with cardiac neurosis (CN), those with organic heart disease (H), and normal subjects (N). Patients were grouped based on exercise tolerance. A E in patient groups was compared with that at the equivalent level of exercise in normalsubjects.
*p<0.05.
tolerance (CN, 55 ± 38; organic heart disease, 44 ± 39 pg/ml); J E in these two groups was significantly higher than that at the end of the third exercise stage in normal subjects (21 ±21 pg/ml). A E in the good tolerance CN group (43±31 pg/ml) was not significantly different from that at the peak exercise in normal subjects (42± 31 pg/ml).
Effects of metoprolol (Fig. 7) After administration of metoprolol, the exercise time was significantly prolonged (from 7.5 ± 4.6 to 10.8 ± 3.4 min). HR at rest significantly decreased from 77+ ll to 62±9 beats/min. HR both at the time equal to the peak exercise time before administration (102± 12 beats/min) and at the peak exercise (124 ± 16 beats/min) was significantly lower than the value at the peak exercise before administration (145 ± 13 beats/min). SBP at rest remained unchanged (135±18 vs 130±30 mmHg). SBP at the time equal to the peak exercise time before administration (156± 16 mmHg)was significantly lower than the value at the peak exercise before administration (183±31 mmHg). SBP at the peak exercise tended to decrease (from 183±31 to 174±29 mmHg, p<0.1). No obvious side effects were observed.
DISCUSSION
In recent years the psychophysiological syndrome represented by CNhas been considered to be a clinical entity based on anxiety. CN is characterized by symptomssuggesting sympathetic hyperactivity.
Plasmacatecholamineconcentrations are considered to be an index of sympathetic activity. Generally, emotional stress induces mainly an increase in epinephrine from adrenal medullae. On the other hand, dynamic exercise stress induces primarily an increase in norepinephrine from postganglionic sympathetic nerves. Several reports showed an increase in plasma norepinephrine and/or epinephrine concentrations at rest in patients with anxiety disorders (4-6). However, only a few reports on the relation between the reduction of workcapacity and the response of sympathetic activity to dynamic exercise stress in patients with CM have been published and the published results are not in agreement (7-9). And there is no report on the comparison of the response of sympathetic activity to exercise between patients with CNand those with organic heart disease. Francis et al (1 1) reported that the plasma norepinephrine concentration is elevated at rest and is more markedly increased at lower levels of dynamic exercise in patients with congestive heart failure than in normal subjects. This increase is attributed to the reflex stimulation of the sympathetic nervous system which maysupport cardiac function. On the other hand, the plasma epinephrine concentration was similar between these two groups at rest, and showed changes during dynamic exercise somewhat similar to those of plasma norepinephrine concentration. However the difference between these two groups at lower levels of dynamic exercise was not as remarkable as plasmanorepinephrine concentration. This finding indicates that adrenal medullae are not major sources of plasma catecholamines during dynamic exercise. The progression of anaerobic metabolism in peripheral organs during exercise is assumed to be a stimulus in the activation of the sympathetic nervous system (12).
In this study we confirmed the reduction of exercise tolerance in patients with CN. Then we divided patients with CNand those with organic heart disease into groups based on exercise tolerance, Fig. 7 . Exercise time, heart rate (HR), and systolic blood pressure (SBP) during multistage treadmill exercise before and after two weeks of administration of metoprolol (40 mg/day) in 8 patients with cardiac neurosis. à" , values before administration; O , values after administration. HRand SBP both at the time equal to the peak exercise time before administration and at the peak exercise after administration were comparedwith the value at the peak exercise before administration. *p <0.05.
catecholamineresponses to exercise amongpatient groups and normal subjects. Patients with CN, those with a reduction in exercise tolerance in particular, showed a hyperkinetic cardiovascular state and sympathetic hyperactivity. The norepinephrine response was augmented in patients with CN, however this augmentation was not as remarkable as that in patients with organic heart disease, while the heart rate response was similar between these two groups. On the other hand, the augmentation of the epinephrine response was greater in patients with CN than in those with organic heart disease. These findings suggest that anxiety augments sympathoneural and sympatho-adrenal activity.
Since Granville-Grossman and Turner (13) reported in 1966 the efficacy of beta blockers on anxiety, many similar reports have been published. Andthe mechanismof the anti-anxiety action of the drug is assumed to be a feedback of the reduction of peripheral symptoms (14). In this study, inspite of the small dose, metoprolol significantly reduced cardiovascular hyperactivity and augmented exercise tolerance in patients with CN. This finding suggests that it is the symptomsinduced by cardiovascular hyperactivity which account for the reduction in exercise tolerance (15).
Thus, we conclude that the hyperactivity of the sympathetic nervous center is related to the augmentation of the cardiovascular and plasma catecholamine responses to exercise in patients with CN and that beta blocker therapy is useful.
